What is the CVR number of Ebumab Sandbox ApS?

Ebumab Sandbox ApS is registered with CVR / Virk under CVR 43575627.

What is the revenue of Ebumab Sandbox ApS?

Ebumab Sandbox ApS reported revenue of DKK -10K in 2024.

Who is the CEO of Ebumab Sandbox ApS?

Johan Henrik Faber is Management of Ebumab Sandbox ApS, in role since 2022.

Who is the chairman of Ebumab Sandbox ApS?

Thomas Dal Stenfeldt Batchelor chairs the board of Ebumab Sandbox ApS, in role since 2022.

Where is Ebumab Sandbox ApS headquartered?

Ebumab Sandbox ApS's registered address is Ole Maaløes Vej 3.

Ebumab Sandbox ApS

APSActive

CVR 43575627Ole Maaløes Vej 3Manufacture of pharmaceutical preparations · NACE 2120Est. 2022— employees

Full Risika report

Revenue 2024

DKK -10K

EBITDA margin

100.0%

-71% vs 2023

Equity ratio

100.0%

Financial strength

Net profit 2024

DKK -8K

-33% vs 2023

EBITDA — year on yearDKK millions

Key figuresAnnual report 2024

Revenue	DKK -10K	—
EBITDA	DKK -10K	-71%
Net profit	DKK -8K	-33%
Total assets	DKK 26K	-23%
Equity	DKK 26K	-23%
Employees	—	—

Item	2023	2024
Revenue	0	-10
Staff expenses	-0	-0
EBITDA	-6	-10
Depreciation & amort.	-0	-0
EBIT	-6	-10
Net financials	0	0
Profit before tax	-6	-10
Tax	-0	-2
Net profit	-6	-8

Item	2023	2024
Total assets	34	26
Equity	34	26
Long-term debt	0	0
Short-term debt	0	0
Total debt	0	0

Name	Role	Member since	Age	Other directorships
JH Johan Henrik Faber Management	Management	2022	—	—
HH Hans Heugh Wandall Chief Executive Officer	Chief Executive Officer	2022	—	—

Name	Role	Member since	Age	Other directorships
SE Søren Erik Bjørn	Board of Directors	2022	—	—
TD Thomas Dal Stenfeldt Batchelor	Chairman	2022	—	—

Shareholder	Type	Ownership	Votes	Since
Ebumab Holding ApS	Company	100.0%	100.0%	2022

Person	Role here	Other companies
Johan Henrik Faber	Management	0 companies
Hans Heugh Wandall	Chief Executive Officer	0 companies
Søren Erik Bjørn	Board of Directors	0 companies
Thomas Dal Stenfeldt Batchelor	Chairman	0 companies

Ebumab Sandbox ApS

APSActive

CVR 43575627Ole Maaløes Vej 3Manufacture of pharmaceutical preparations · NACE 2120Est. 2022— employees

Full Risika report

Revenue 2024

DKK -10K

EBITDA margin

100.0%

-71% vs 2023

Equity ratio

100.0%

Financial strength

Net profit 2024

DKK -8K

-33% vs 2023

EBITDA — year on yearDKK millions

Key figuresAnnual report 2024

Revenue	DKK -10K	—
EBITDA	DKK -10K	-71%
Net profit	DKK -8K	-33%
Total assets	DKK 26K	-23%
Equity	DKK 26K	-23%
Employees	—	—